BNTC vs. SLGL, MEIP, SYBX, TCRT, RNXT, NNVC, CPIX, GDTC, BFRG, and GLYC
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Synlogic (SYBX), Alaunos Therapeutics (TCRT), RenovoRx (RNXT), NanoViricides (NNVC), Cumberland Pharmaceuticals (CPIX), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
Benitec Biopharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -61.52% beat Benitec Biopharma's return on equity.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Benitec Biopharma has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
In the previous week, Benitec Biopharma had 2 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Benitec Biopharma and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.96 beat Benitec Biopharma's score of 0.73 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.
Benitec Biopharma presently has a consensus price target of $16.00, indicating a potential upside of 97.04%. Sol-Gel Technologies has a consensus price target of $8.00, indicating a potential upside of 1,060.35%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Benitec Biopharma.
Benitec Biopharma has higher earnings, but lower revenue than Sol-Gel Technologies.
Benitec Biopharma received 34 more outperform votes than Sol-Gel Technologies when rated by MarketBeat users. Likewise, 63.73% of users gave Benitec Biopharma an outperform vote while only 63.09% of users gave Sol-Gel Technologies an outperform vote.
Summary
Sol-Gel Technologies beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
